Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Cancer Survivorship Branch, National Cancer Control Institute, National Cancer Center, Goyang, Korea.
Crit Care Med. 2019 May;47(5):e386-e393. doi: 10.1097/CCM.0000000000003654.
Although the effect of antihypertensive agents on sepsis has been studied, evidence for survival benefit was limited in the literature. We investigated differences in sepsis-related outcomes depending on the antihypertensive drugs given prior to sepsis in patients with hypertension.
Population-based cohort study.
Sample cohort Database of the National Health Insurance Service from 2003 to 2013 in South Korea.
Patients over 30 years old who were diagnosed with sepsis after receiving hypertension treatment.
None.
Primary outcomes, 30-day and 90-day mortality rates, were analyzed for differences among three representative antihypertensive medications: angiotensin- converting enzyme inhibitors or angiotensin II receptor blockers, calcium channel blockers, and thiazides. In total, 4,549 patients diagnosed with hypertension prior to hospitalization for sepsis were identified. The 30-day mortality was significantly higher among patients who did not receive any medications within 1 month before sepsis (36.8%) than among patients who did (32.0%; p < 0.001). The risk for 90-days mortality was significantly lower in prior angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker users (reference) than in other drug users (odds ratio, 1.27; 95% CI, 1.07-1.52). There was no difference in the risk for 30-day and 90-day mortality depending on whether calcium channel blockers or thiazides were used. Use of calcium channel blockers was associated with a decreased risk for inotropic agent administration, compared with those of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (odds ratio, 1.23; 95% CI, 1.05-1.44) and thiazides (odds ratio, 1.33; 95% CI, 1.12-1.58).
In patients with sepsis, lower mortality rate was associated with prior use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers not with use of calcium channel blockers or thiazides. The requirement of inotropic agents was significantly lower in prior use of calcium channel blockers, although the survival benefits were not prominent.
尽管已有研究探讨了降压药物对脓毒症的影响,但相关文献中关于生存获益的证据有限。我们调查了高血压患者在发生脓毒症之前使用的降压药物对脓毒症相关结局的影响。
基于人群的队列研究。
韩国国民健康保险服务 2003 年至 2013 年的样本队列数据库。
在接受高血压治疗后被诊断为脓毒症且年龄超过 30 岁的患者。
无。
主要结局为 30 天和 90 天死亡率,分析了三种代表性降压药物之间的差异:血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂、钙通道阻滞剂和噻嗪类利尿剂。共确定了 4549 例在因脓毒症住院前被诊断为高血压的患者。在脓毒症前 1 个月内未服用任何药物的患者 30 天死亡率(36.8%)明显高于服用药物的患者(32.0%;p<0.001)。与其他药物使用者相比,先前使用血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂的患者(参考)90 天死亡率风险显著降低(比值比,1.27;95%可信区间,1.07-1.52)。使用钙通道阻滞剂或噻嗪类利尿剂与 30 天和 90 天死亡率的风险无差异。与血管紧张素转换酶抑制剂或血管紧张素 II 受体阻滞剂相比,使用钙通道阻滞剂与正性肌力药物的使用减少相关(比值比,1.23;95%可信区间,1.05-1.44),与噻嗪类利尿剂相比(比值比,1.33;95%可信区间,1.12-1.58)。
在脓毒症患者中,较低的死亡率与先前使用血管紧张素转换酶抑制剂和血管紧张素 II 受体阻滞剂相关,而与使用钙通道阻滞剂或噻嗪类利尿剂无关。虽然生存获益不明显,但先前使用钙通道阻滞剂时,正性肌力药物的需求明显降低。